Recent Updates — OTLC

On October 7 and 8, 2026, Oncotelic Therapeutics representatives presented information regarding its PDAOAI platform and hepatocellular carcinoma (HCC) research at the Drug Discovery 2026 conference in Burlingame, California. The presentations detailed the platform's search capabilities and a four-gene mTOR-related signature associated with overall survival in exploratory analyses. The company also described an initiative inviting researchers to propose therapeutic projects using PDAOAI for potential startup funding. Oncotelic Therapeutics operates as a biotechnology company focused on drug discovery platforms and oncology research.

On August 3, 2026, Oncotelic Therapeutics, Inc. entered into a Securities Purchase Agreement with Pacific Pier Capital II, LP, issuing a convertible promissory note with an aggregate gross principal amount of $178,410. The note carries a 12% original issue discount and a 12% annual interest rate, maturing one year from issuance or upon acceleration due to default. Conversion is permitted at the holder's option into common stock at $0.06 per share or 85% of the lowest traded price over the preceding ten trading days. The company also issued 500,000 commitment shares to the investor. Oncotelic Therapeutics operates in the biotechnology industry, focusing on drug discovery and development.

On July 10, 2026, Oncotelic Therapeutics, Inc. approved the issuance of 17,796 restricted stock units (RSUs) to directors, officers, employees, and advisors. Each RSU entitles the holder to one share of Series A Convertible Preferred Stock, which is convertible into 1,000 shares of common stock. Vesting is contingent upon the company's common stock being uplisted to a national stock exchange by June 30, 2027, and the recipient remaining in service for six months post-uplisting. Key recipients include CEO Vuong Trieu, Ph.D., who was granted 2,000 RSUs. Oncotelic Therapeutics, Inc. is a biotechnology company.